PALI - Palisade Bio, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$1.50
DETAILS
HIGH:
$1.50
LOW:
$1.50
MEDIAN:
$1.50
CONSENSUS:
$1.50
DOWNSIDE:
23.08%
About Palisade Bio, Inc. (https://www.palisadebio.com)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| J. D. Finley | Chief Executive Officer, Chief Financial Officer & Director | 1958 | $1,006,300 USD |
| Mitchell Lawrence Jones | President & Chief Medical Officer | 1977 | $704,000 USD |
| Adarsh Patel | Head of Chemistry, Manufacturing & Controls | – | – |
| Daniel J. Larkins | Head of Global Regulatory Affairs | – | – |
| James Izanec | VP & Head of Clinical Development | – | – |
| Joerg Heyer | Head of Translational Science & Medicine | – | – |
| Ramesh C. Donthamsetty | Head of Corporate Development & Investor Relations | – | – |
| Ryker Willie | Senior Vice President of Finance & Corporate Controller | – | – |
| Sharon Skare | Vice President & Global Head of Clinical Operations | – | – |